NCT00000466 is a Phase 3 clinical trial of estrogens, conjugated in Bone Diseases, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT00000466?

NCT00000466 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What drugs are being tested in NCT00000466?

Interventions in NCT00000466: estrogens, conjugated, medroxyprogesterone, progesterone, estrogen replacement therapy.

What condition does NCT00000466 study?

NCT00000466 studies Bone Diseases, Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Heart Diseases, Hypercholesterolemia, Hypertension, Myocardial Ischemia, Osteoporosis, Thrombosis, Postmenopause.

Is NCT00000466 still recruiting?

NCT00000466 is currently completed. Last updated 12 May 2016.

Last reviewed 2016-05-12 · How we verify

NCT00000466

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postmenopausal Estrogen/Progestin Interventions (PEPI)

Completed Phase 3 Last updated 12 May 2016

What this trial tests

Phase 3 trial testing estrogens, conjugated in Bone Diseases. Completed in 1 October 2000.

Timeline

1 September 1987

1 October 2000

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Masking	double
Primary purpose	prevention
Start date	1 September 1987
Estimated completion	1 October 2000

Drugs / interventions tested

estrogens, conjugated — full drug profile →
medroxyprogesterone
progesterone (Progesterone plus HCG) — full drug profile →
estrogen replacement therapy

Conditions studied

Bone Diseases — all drugs for Bone Diseases →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Coronary Disease — all drugs for Coronary Disease →
Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Adults 45 to 64, female only, with Bone Diseases or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bone-density testing interval and transition to osteoporosis in older women.
Gourlay ML, Fine JP, Preisser JS, May RC, et al · · 2012 · cited 180× · PMID 22256806 · DOI 10.1056/nejmoa1107142

Verify or expand the search:

Other recruiting trials for Bone Diseases

Currently open trials in the same condition.

NCT06745791 — Clinical Validation of BoneMRI in the Spine · recruiting
NCT03571191 — Denosumab Treatment for Fibrous Dysplasia · Phase 2 · active not recruiting

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00000466 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 12 May 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00000466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing